89 results about "Right ventricles" patented technology

A system for determining fluid responsiveness of a patient includes a hemodynamic sensor that produces, on an ongoing basis, a hemodynamic sensor signal representative of a right ventricular pressure (RVP) waveform of the patient and an integrated hardware unit. The integrated hardware unit includes a processor, a memory, and a display including a user interface. The memory includes instructions that, when executed by the processor, cause the system to receive the hemodynamic sensor signal representative of the RVP waveform of the patient, convert the RVP waveform of the patient into an estimate of a blood flow waveform of the patient, determine a stroke volume variation (SVV) of the patient based on the estimate of the blood flow waveform of the patient to generate a determined SVV, and output, to the display, an indication of a fluid responsiveness status of the patient that is based on the determined SVV.

Disclosed are a method for presenting cardiac myocardial strain and an ultrasound imaging apparatus, comprising: acquiring image data of myocardial segments of both left and right ventricles, and processing this data to obtain motion parameters of both left and right ventricular myocardial segments. A composite bull's-eye plot containing left and right ventricular bull's-eye subplots is displayed, wherein the left ventricular bull's-eye subplot comprises multiple left ventricular myocardial regions corresponding to the left ventricular myocardial segments and presenting motion parameters of the left ventricular myocardial segment; and the right ventricular bull's-eye subplot comprises a right ventricular myocardial region corresponding to the right ventricular myocardial segments that exclude some / all shared segments with the left ventricle and presenting motion parameters of the right ventricular myocardial segment. This configuration enables users to observe motion parameters of both ventricular myocardial segments, thereby providing comprehensive understanding of cardiac myocardial strain while enhancing clinical efficiency for doctors.

The invention provides a self-adaptive control method and device for a double-ventricle auxiliary system. The method comprises the steps that target aortic pressure detected by a first pressure sensor, target left ventricular end diastolic pressure detected by a second pressure sensor, target right atrial pressure detected by a third pressure sensor and target pulmonary artery pressure detected by a fourth pressure sensor are obtained; and determining a strategy for adjusting the left ventricular assist device or the right ventricular assist device according to the target left ventricular end diastolic pressure, the target right ventricular pressure and the target pulmonary arterial pressure when the peripheral perfusion of the target user is insufficient or the lung is over-perfused. The pressure sensors are arranged to detect the pressure of the inlets and the outlets of the left ventricular assist device and the right ventricular assist device, whether adverse events such as peripheral insufficiency or pulmonary hyperperfusion occur to a user or not is judged according to the detected pressure, and then the adverse events are relieved or even solved by adjusting the rotating speeds of the left ventricular assist device and the right ventricular assist device. And the safety of the user is greatly improved.

The invention relates to an application of a THBS4 inhibitor in preparation of a medicine for preventing and / or treating pulmonary arterial hypertension. Three pulmonary arterial hypertension rat models (a hypoxia induction model, a hypoxia combined SUGEN induction model and a monocrotaline induction model) are constructed, the expression change of THBS4 is verified through qRT-PCR and western blot, and the correlation between the expression level of THBS4 and pulmonary arterial hypertension is verified in combination with in-vitro cell experiments and in-vivo intervention. Results show that THBS4 is remarkably up-regulated in pulmonary arteries of the three models, the expression level of THBS4 is positively correlated with the severity of diseases, and THBS4 is an important regulatory factor for promoting vascular remodeling in pulmonary arterial hypertension. In vivo, by knocking down THBS4, pulmonary vascular remodeling and right ventricular hypertrophy are remarkably relieved, and it is prompted that THBS4 inhibitors show good application prospects in the aspect of preventing and / or treating pulmonary arterial hypertension.

A system for determining placement of a catheter in a patient includes a hemodynamic sensor and a display. The hemodynamic sensor produces a signal representative of a right ventricular pressure waveform of the patient. The catheter is connected to the hemodynamic sensor. The system further includes one or more processors and computer-readable memory encoded with instructions that, when executed by the one or more processors, cause the system to receive the signal representative of the right ventricular pressure waveform and extract features from the right ventricular pressure waveform. The instructions further cause the system to compare the features to one or more value ranges of the features to determine that the catheter is correctly placed when values of the features are within the one or more value ranges or that the catheter is incorrectly placed, is not properly connected to the system, or signal quality issues are occurring.

This invention discloses a floating temporary pacing lead with a pig-tail shaped tip, comprising a lead body, an air bladder and a conductive area at the tip of the lead body, an inflation tube and an electrode wire along the length of the lead body, the inflation tube communicating with the air bladder, and the electrode wire connected to the conductive area; the tip of the lead body is bent inward to form an unclosed loop pig tail loop, the air bladder is located inside the pig tail loop, and the conductive area is located outside the pig tail loop; by providing an inwardly bent, unclosed loop pig tail loop at the tip of the lead body, this application changes the contact between the lead body tip and the ventricular wall from point contact to surface contact, increasing the contact area between the pacing lead and the right ventricle, and the contact surface between the pacing lead and the ventricular wall is a smooth curve, avoiding complications such as ventricular wall perforation.

An implantable lead for use with an implantable medical device (IMD) includes a tubular lead body having a proximal portion including a proximal end, a distal portion including a distal end opposite the proximal end, and an intermediate portion between the proximal portion and the distal portion. A helical electrode extends distally from the distal end of the tubular lead body. At least one atrial electrode is disposed in the intermediate portion of the tubular lead body. At least one electrical conductor extends through the tubular lead body and is mechanically and electrically coupled to the helical electrode and the at least one atrial electrode. The intermediate portion may have a pre-formed bend configured to urge the at least one atrial electrode against a surface of the right atrium when the lead is implanted. A distal pre-formed bend located in the distal portion of the tubular lead body may be configured to bias a plurality of pacing / sensing electrodes towards a surface of a right ventricle. A distal pre-formed bend located in the distal portion of the tubular lead body may be configured to bias the helical electrode and at least one pacing / sensing against a surface of a right ventricle.

A system for monitoring right ventricular systolic dysfunction includes a hemodynamic sensor that produces a hemodynamic sensor signal representative of a right ventricular pressure waveform of the patient, a display, one or more processors, and computer-readable memory. The computer-readable memory is encoded with instructions that, when executed by the one or more processors, cause the system to receive the hemodynamic sensor signal representative of the right ventricular pressure waveform of the patient, extract right ventricular peak systolic pressure and right ventricular end diastolic pressure from the right ventricular pressure waveform of the patient, determine a ratio of right ventricular peak systolic pressure over right ventricular end diastolic pressure, and output the ratio of right ventricular peak systolic pressure over right ventricular end diastolic pressure to the display for monitoring the presence of right ventricular systolic dysfunction based on the ratio of peak systolic pressure over end diastolic pressure.

The utility model discloses a fixing strap for a temporary pacemaker, which comprises a shoulder strap and a binding strap, an extension bag is sewed below the shoulder strap, a zipper is sewed on the surface of the extension bag, a weight is stored in the extension bag, and a binding surface is arranged at the bottom end of the extension bag; a traction piece is arranged on the surface of the extension bag and used for changing the position of the extension bag, and the fixing band is used in cooperation with the fixing band at the position, close to the apex of the right ventricle, of the extension bag after being worn, so that the fixing band can keep a good attaching effect whether daily activities or mild exercises are carried out; and the risk of complications caused by displacement of the pacemaker or poor contact of the electrodes is reduced. The bonding head is bonded to the bonding female end area by pulling the traction belt, it can be ensured that the position of the extension bag after adjustment is kept stable, that is, the position of the extension bag is changed through traction of the traction belt, and the position of the extension bag is accurately adjusted.

The application relates to a method for constructing a rat model of chronic obstructive pulmonary disease (COPD) related pulmonary arterial hypertension and application thereof, and belongs to the technical field of animal disease model construction. The method selects 6-8-week-old, 220+ / -10g healthy male SD rats, and all the rats are adaptively fed in a standard SPF level animal room for 7 days; then the rats are divided into a Con group and a COPD-PH group; the rats in the COPD-PH group are given 1mg / mL lipopolysaccharide by airway instillation on the first day and the 14th day; the rats are placed in a self-made whole-body inhalation smoking box for 1h every day from the 2nd day to the 13th day and from the 15th day to the 30th day; the rats enter a low-oxygen box for 8h every day during the light period from the 2nd day to the 13th day and from the 15th day to the 30th day; the rat model can simultaneously reproduce the characteristics of COPD and typical changes of pulmonary arterial hypertension, the right ventricular systolic pressure can be stably increased to 40-50mmHg, the right ventricular hypertrophy index can reach 0.40-0.50, the pulmonary vascular remodeling and inflammation are significant, and various indexes are stable and good in repeatability.

An arrhythmia type inference device includes: an obtaining section that obtains a target signal waveform indicating a time-series change in the area of a region, which is at least one of a left atrium, a left ventricle, a right atrium, and a right ventricle, the target signal waveform being generated by analyzing an image of a heart of a target subject; and an inference section that infers the type of tachyarrhythmia suffered by the target subject based on the shape of the target signal waveform having a frequency in a frequency band higher than a reference frequency band predetermined as a normal range. This allows the arrhythmia type inference device to accurately infer the type of tachyarrhythmia from the image obtained by image-capturing of the heart.

In some aspects, the invention teaches pharmaceutical compositions that include a TGF-β ligand trap, and methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-β signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-β ligand trap to reduce right ventricular systolic pressure in a subject.

In some aspects, the invention teaches pharmaceutical compositions comprising a TGF-beta ligand trapping agent, and methods of using the TGF-beta ligand trapping agent to treat, prevent, or reduce the rate of progression of pulmonary hypertension (PH). The invention also provides methods of using the TGF-beta ligand trapping agents to treat, prevent, or reduce the rate of progression of a variety of disorders, the conditions include, but are not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-beta signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using the TGF-beta ligand trapping agent to reduce right ventricular systolic pressure in a subject.

Described herein are pumps that linearly reciprocate to assist with circulating blood within the body of a patient. Red blood cell damage may be avoided or minimized by such linear pump movement. The linearly reciprocating movement may also generate a pulsatile pumping cycle that mimics the natural pumping cycle of the heart. The pumps may be configured to reside at various body locations. For example, the pumps may be situated within the right ventricle, the left ventricle, the ascending aorta, the descending aorta, the thoracic aorta, or the abdominal aorta. In some instances, the pump may be deployed within the venous circulation. In other instances, the pump may reside outside the patient.

A system for determining a global hypoperfusion index (GHI) includes an arterial blood pressure sensor, a ventricular blood pressure sensor, an oximetry module, and an integrated hardware unit including a system processor and a system memory. The system memory includes instructions that cause the system to receive arterial hemodynamic data, ventricular hemodynamic data, and blood oxygen saturation data. One or more right ventricular pressure features, one or more pulmonary artery pressure features, one or more cardiac output parameters, and one or more venous oxygen saturation parameters are derived from the arterial hemodynamic data, the ventricular hemodynamic data, and the blood oxygen saturation data. The GHI is derived by using a predictive decision model based upon the one or more right ventricular pressure features, the one or more pulmonary artery features, the one or more cardiac output parameters, and the one or more venous oxygen saturation parameters.

Methods and systems are provided for a rate adaptive bi-ventricular fusion pacing. The methods and systems deliver a first pulse at a left ventricular (LV) lead and a second pulse at a right ventricular (RV) lead based on a paced atrio-ventricular (AV) delay. The first pulse timed to be delivered concurrently with an intrinsic ventricular conduction. The methods and systems further repeat the delivery of the first pulse and the second pulse for a predetermined number of cycles. Additionally, the methods and systems measure an intrinsic AV conduction interval, and adjust the paced AV delay based on the intrinsic AV conduction interval and a negative hysteresis delta.

An ultrasound imaging and backscatter system includes an ICE ultrasound catheter having an ultrasound pMUT transducer array disposed within a distal end of the ultrasound catheter and including a plurality of transducer array elements disposed on a substrate. One end of the catheter shaft is connected to the handle assembly and the other end is connected to the ultrasonic transducer array. The catheter shaft accommodates an electronic flexible cable in communication with the signal trace and directs each of the plurality of transducer array elements to transmit and receive an ultrasound beam, receives at least one signal from the plurality of transducer array elements, and constructs at least one image characterizing one or more tissue components of the scanned object. An ultrasound imaging system is used to measure tissue thickness, tissue scar, and lesion assessment for left atrium, right atrium, left ventricle, and right ventricle tissue wall characteristics and other intracardiac tissue anomalies.

The present invention belongs to the field of pulmonary vascular disease treatment, and specifically discloses a TGF-β receptor inhibitor for the treatment of pulmonary hypertension. In the rat pulmonary hypertension model induced by monocrotaline (MCT), after using the preparation, the right ventricular systolic pressure (RVSP), right ventricular hypertrophy (Fulton index), pulmonary vascular resistance and vascular wall thickness of the rat can be reversed and reduced, and the survival rate of monocrotaline (MCT)-induced pulmonary hypertension rats can be prolonged. Compared with the modeling group, the expression of IL-17, IL-6 and GM-CSF inflammatory factors in the lung tissue of the preparation-treated group was significantly reduced, and the expression of extracellular matrix-related genes CTGF, Fn1 and Col1α1 also decreased. The preparation can significantly alleviate the pulmonary hypertension in rats induced by monocrotaline (MCT), showing good therapeutic effect and application prospects.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for preventing and treating ventricular remodeling and a preparation method thereof. The traditional Chinese medicine composition for preventing and treating ventricular remodeling is prepared from the following raw materials: 25 to 35 parts of radix astragali seu hedysari, 10 to 15 parts of cassia twig, 10 to 15 parts of peach kernel, 12 to 18 parts of flos carthami and 7 to 11 parts of semen lepidii. According to the traditional Chinese medicine composition, the left ventricular posterior wall thickness, the ventricular septum thickness and the left ventricular end diastolic inner diameter are obviously increased, the left ventricular end systolic inner diameter, the left ventricular mass index and the right ventricular mass index are obviously reduced, and it is prompted that the traditional Chinese medicine composition can inhibit ventricular remodeling of rats suffering from ischemic cardiomyopathy.

The present application relates to a kind of self-balancing double-cavity nutational blood pump, including pump cavity, pump cavity is separated into right ventricular pump cavity and left ventricular pump cavity of upper and lower distribution by stator isolation base, right ventricular pump cavity is equipped with right ventricular nutational disc, left ventricular pump cavity is equipped with left ventricular nutational disc;Center hole of stator isolation base is equipped with coaxial transmission main shaft through, coaxial transmission main shaft upper end is connected with right ventricular nutational disc by right ventricular eccentric drive sleeve, lower end is connected with left ventricular nutational disc by left ventricular eccentric drive sleeve, the inclination of right ventricular eccentric drive sleeve and left ventricular eccentric drive sleeve in circumferential direction is 180 degrees apart;Coaxial transmission main shaft drives right ventricular nutational disc and left ventricular nutational disc synchronous nutational swing of swing.The mechanical self-balancing of right ventricular pump cavity, left ventricular pump cavity is realized using 180° phase difference conjugate drive, the inherent violent mechanical vibration of single-disc nutational pump is eliminated from physical root, greatly guarantee the working stability of whole artificial heart implantation in human body and the comfort of patient.

The invention relates to the technical field of internal medicine operations, and discloses an ectopic implantation valve stent system for treating tricuspid regurgitation, which comprises a right atrium and a right ventricle fixedly connected to the right atrium; the tricuspid valve is fixedly connected between the right atrium and the right ventricle; the cannula assembly is connected into the tricuspid valve in a sliding mode; the supporting assembly is fixedly connected to the right atrium; the bracket assembly is fixedly connected to the supporting assembly; the valve assembly is fixedly connected to the supporting assembly; one part of the supporting assembly is fixedly connected to the right atrium, and the other part of the supporting assembly is fixedly connected to the tricuspid valve. Liquid medicine is injected into the curing tube through the sealing nozzle through the injection tube, after the liquid medicine and the curing liquid are mixed, the curing liquid is cured, meanwhile, barbed nails on the fixing plate layer are used for puncturing the root of the tricuspid valve for further fixing, the stent assembly and the valve assembly are not prone to falling off after being installed, the service time is longer, and the fixing effect is better. Patients do not need to have mental stress due to the falling risk of the support assembly.

A system for improving the function of a defective heart includes a tubular membrane, a replacement valve, a set of one or more inlets, and a set of one or more outlets. The tubular membrane encompasses (i) a first chamber of the system, shaped to conform to an interior region of a right atrium of the heart, and (ii) a second chamber of the system, shaped to conform to an interior region of a right ventricle of the heart. The replacement valve is configured to separate the first chamber from the second chamber, and has leaflets for providing flow in only one direction. The one or more inlets connect the first chamber with a first portion of cardiovascular anatomy, and the one or more outlets connect the second chamber with a second portion of cardiovascular anatomy.

The present invention relates to a system for attaching a heart valve, the function of which is to attach a heart valve to a cardiac prosthesis intended to be implanted in a patient's pericardial cavity and to replace the patient's natural left and right ventricles, the system comprising a male ring with spikes and a cooperating part with openings, the male ring or the cooperating part being intended to be fixed to the cardiac prosthesis, the spikes and the openings being configured such that the spikes pass through a collar of the heart valve and enter the openings at the attachment position.

A system for monitoring right ventricular systolic dysfunction includes a hemodynamic sensor that generates a hemodynamic sensor signal representative of a right ventricular pressure waveform of a patient, a display, one or more processors, and a computer readable memory. The computer-readable memory is encoded with instructions that, when executed by the one or more processors, cause the system to receive a hemodynamic sensor signal representative of a right ventricular pressure waveform of the patient, extract a right ventricular peak systolic pressure and a right ventricular end diastolic pressure from the right ventricular pressure waveform of the patient, and transmit the extracted right ventricular peak systolic pressure and right ventricular end diastolic pressure to the one or more processors. A ratio of the right ventricular peak systolic pressure to the right ventricular end diastolic pressure is determined, and the ratio of the right ventricular peak systolic pressure to the right ventricular end diastolic pressure is output to a display to monitor the presence of the right ventricular systolic dysfunction based on the ratio of the peak systolic pressure to the end diastolic pressure.

The embodiment of the application provides a right ventricular assist system and a control method of a right ventricular assist device. The right ventricular assist device comprises a blood-out cage, a blood-in cage, a pumping assembly and a driving assembly. The driving assembly, the pumping assembly and the blood-in cage are located in the inferior vena cava, and the blood-out cage is located in the pulmonary artery. The driving assembly drives the pumping assembly to rotate in the clockwise direction, pushes the blood from the blood-in cage into the blood-out cage, and then into the pulmonary artery. The target motor in the driving assembly is a brushless hollow cup motor, which is composed of a rotor and a stator. The angle between the magnetic induction lines of the rotor magnetic field and the stator magnetic field is a fixed angle, which is an angle between 40 degrees and 50 degrees. The controller comprises a level determination module, a current determination module, a current mapping module, a current fusion module, a voltage determination module and a motor control module. By using the embodiment, the control of the right ventricular assist device can be adapted to the real-time change state of the heart.

An implantable medical system may provide atrioventricular synchronous pacing using the ventricular septal wall. The system may include a ventricular electrode coupled to an intracardiac housing or a first medical lead implantable in the ventricular septal wall of the patient's heart to deliver cardiac therapy to or sense electrical activity of the left ventricle of the patient's heart and a right atrial electrode coupled to a leadlet or second medical lead to deliver cardiac therapy to or sense electrical activity of the right atrium of the patient's heart. A right ventricular electrode may be coupled to the intracardiac housing or the first medical lead and implantable in the ventricular septal wall of the patient's heart to deliver cardiac therapy to or sense electrical activity of the right ventricle of the patient's heart.

The application provides a blood supply and demand balance adjustment method and system of a total artificial heart and the total artificial heart, and belongs to the technical field of medical devices. The blood supply and demand balance adjustment method of the total artificial heart obtains the real-time blood supply and demand balance index of the total artificial heart, compares the blood supply and demand balance index with the blood supply and demand balance index threshold obtained and set in advance, and obtains the blood supply information of the total artificial heart to the human body. In the case that the blood supply information of the total artificial heart to the human body shows that the blood supply of the left ventricle of the total artificial heart and the right ventricle of the total artificial heart to the human body is unbalanced, the running speed of one of the left and right ventricles is changed based on the correlation between the running speed of the power system and the blood pumping capacity of the ventricle, and the blood pumping capacity of the left and right ventricles is also changed, so that the blood supply of the left and right ventricles can be accurately adjusted in real time to achieve balance.

Devices, systems, and methods provide measurements of continuous cardiac output (CCO). A pulmonary artery (PA) catheter—for example, a Swan-Ganz catheter—can be utilized to obtain multiple pressure measurements simultaneously from different locations within the circulatory system, such as in a pulmonary artery, right atrium, right ventricle, vena cava, etc. Continuous pressure measurements from multiple points can provide estimates of heart rate and stroke volume allowing computation of cardiac output along with each beat of the heart without the need for thermodilution.